Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 724

Showing 26-50 of 724 citing articles:

Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer
Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 93, pp. 105401-105401
Open Access | Times Cited: 14
Decomposable Nanoagonists Enable NIR‐Elicited cGAS‐STING Activation for Tandem‐Amplified Photodynamic‐Metalloimmunotherapy
Xun Guo, Peng Tu, Xiaoting Wang, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 14
“Triple-Punch” Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy
Chenhong Zhang, Shuangshuang Tang, Meilin Wang, et al.
ACS Nano (2024)
Closed Access | Times Cited: 12
MRI‐Guided Tumor Therapy Based on Synergy of Ferroptosis, Immunosuppression Reversal and Disulfidptosis
Shuai Guo, Zongheng Li, Ruilong Zhou, et al.
Small (2024) Vol. 20, Iss. 29
Closed Access | Times Cited: 12
Simultaneous blockade of the CD73/EGFR axis inhibits tumor growth
Keivan Ardeshiri, Hadi Hassannia, Ghasem Ghalamfarsa, et al.
IUBMB Life (2025) Vol. 77, Iss. 1
Closed Access | Times Cited: 1
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
Song‐Yang Wu, Ying Xu, Li Chen, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 60
Co‐delivery CPT and PTX prodrug with a photo/thermo‐responsive nanoplatform for triple‐negative breast cancer therapy
Wenhui Zhou, Xiaodong Ma, Jie Wang, et al.
Smart Medicine (2022) Vol. 1, Iss. 1
Open Access | Times Cited: 60
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 59
Chitosan: A versatile bio-platform for breast cancer theranostics
Vijay Sagar Madamsetty, Shima Tavakol, Saeid Moghassemi, et al.
Journal of Controlled Release (2021) Vol. 341, pp. 733-752
Closed Access | Times Cited: 55
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 593-605
Open Access | Times Cited: 49
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade
Xuewei Bai, Yanmei Zhou, Yuki Yokota, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 39
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Jianzhang Yang, Yu Chang, Jean C. Tien, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 11066-11083
Open Access | Times Cited: 38
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Laura M. Spring, Yael Bar, Steven J. Isakoff
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 6, pp. 723-734
Open Access | Times Cited: 37
Manganese-enriched photonic/catalytic nanomedicine augments synergistic anti-TNBC photothermal/nanocatalytic/immuno-therapy via activating cGAS-STING pathway
Yi Zheng, Jing Chen, Xinran Song, et al.
Biomaterials (2022) Vol. 293, pp. 121988-121988
Open Access | Times Cited: 36
Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals
Meixi Hao, Lulu Zhu, Siyuan Hou, et al.
ACS Nano (2023) Vol. 17, Iss. 2, pp. 1663-1680
Closed Access | Times Cited: 34
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
Laura M. Spring, Sara M. Tolaney, Geoffrey Fell, et al.
Annals of Oncology (2023) Vol. 35, Iss. 3, pp. 293-301
Open Access | Times Cited: 33
Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer
Beibei Guo, Yan Qu, Yinping Sun, et al.
Bioactive Materials (2023) Vol. 25, pp. 61-72
Open Access | Times Cited: 31
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
Xiaoxiao Wang, L. Collet, Mattia Rediti, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 953-953
Open Access | Times Cited: 29
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1597-1597
Open Access | Times Cited: 29
The Role of Isoflavones in the Prevention of Breast Cancer and Prostate Cancer
T. Pejcic, Milica Zeković, Uroš Bumbaširević, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 368-368
Open Access | Times Cited: 27
Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1
Jingjie Yi, Huan Li, Bo Chu, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 7, pp. 1799-1810
Open Access | Times Cited: 25
Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review
Mina Hosseini, Simin Seyedpour, Behzad Khodaei, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 146-146
Open Access | Times Cited: 24
Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer
Daniel J. Elson, Siva K. Kolluri
Biology (2023) Vol. 12, Iss. 4, pp. 526-526
Open Access | Times Cited: 24
Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance
Chanjuan Zheng, Xu Xi, Muyao Wu, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 24

Scroll to top